SUMMARY
INTRODUCTION
Schizophrenia is a long-term, recurrent disorder characterized by episodes of acute psychosis and their remission (Clementz et al. 2015) . While the clinical presentation may be very heterogeneous, generally, the illness usually starts with a prodromal period followed by the first episode of acute psychosis. It is characterized by symptoms that can be divided into five dimensions: positive, negative, neurocognitive, affective and psychomotor. During the following months most patients achieve remission of the first episode usually followed by reoccurring periods of acute psychosis and remission until a stage of residual phase is reached (Wiersma et al. 1998) . In contrast to the first episode, every new episode usually requires more time and more medication to achieve remission .
Neurocognitive symptoms are often defined as the core feature of schizophrenia (Barder et al. 2013 ). Deficits in cognitive functioning are typically 0.5 to 2 standard deviations below healthy control group across a number of cognitive domains (Gold 2004 From the clinical point of view, neurocognitive symptoms are relevant as they may be regarded as the most resistant to pharmacological treatment compared to all other symptom dimensions (Ahmed & Bhat 2014 , Trampush et al. 2015 . Moreover, they seem to be connected with different aspects of functionality as an objective measure and quality of life as a subjective measure of illness outcome (Lepage et al. 2014 , Mesholam-Gately et al. 2009 , Rodriguez et al. 2015) . Neurocognitive decline is directly associated with poor psychosocial functioning, low work productivity and high absenteeism of persons with schizophrenia and consequently present a significant emotional and economic burden to them and the society (Chong et al. 2016 , Fett et al. 2011 , Kane & Lencz 2008 , Rodriguez et al. 2015 .
Despite the clinical relevance of neurocognitive decline in schizophrenia, there is a number of uncertainties in the occurrence and progression of these symptoms in schizophrenia. First, it is rather unclear which are the factors influencing neurocognitive decline over time in patients with schizophrenia (SCH). In the current literature, neurocognitive decline over time in SCH was found to be associated with male gender, unemployment, poor premorbid achievement, later age of onset, presence of negative symptoms (Bora 2015 , Bora et al. 2009 ), suicidality (Ventriglio et al. 2016 ) and lower achievement of stable remission during the first year of illness , Rund et al. 2016) .
Second, it is unclear whether there are differences in the speed and severity of neurocognitive decline among different neurocognitive functions. Although majority of longitudinal studies report relative stability of neurocognitive decline during the course of illness (Hoff et al. 2005 , Rund et al. 2016 ), some report different changes in specific neurocognitive domains. According to Barder et al. (2013) working memory significantly improved during the first two years of follow-up of patients with first episode of psychosis (FEP), with no further changes in the following three years. However, other authors report decline in some of the domains, e.g. in visuospatial abilities (Stirling et al. 2003) or memory and speed of processing (Øie et al. 2008 ). Apart from a number of factors that can explain these results, the heterogeneity of assessment methods and applied neurocognitive tests may further contribute to it. Generally, different neurocognitive tests are used for the assessment of specific neurocognitive domains (Mesholam-Gately et al. 2009 ). In order to avoid multiplication, attempts were made to produce neurocognitive test batteries, for example with The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (Nuechterlein & Green 2006) . However, the dimensional structure of these batteries is still not consistently reproduced, at least in the international, European cultural context (Mohn et al. 2017 ). Thus, the influence of different cultural context on results of psychological tests which are translated from one country to another is not defined.
To overcome these limitations, we conducted this study aiming to construct comprehensive neurocognitive profiles in schizophrenia, by applying a number of individual neurocognitive tests previously used in the Croatian population. Tests assessed five neurocognitive domains in two large different groups of patients with schizophrenia: the patients with the first episode and patients with multiple episodes. Secondly, we attempted to analyze the correlations of obtained profiles with clinical features of patients and their perceived quality of life.
SUBJECTS AND METHODS

Study protocol
This cross-sectional study was conducted at three Croatian hospitals: Zagreb University Hospital Centre, Neuropsychiatric Hospital Dr. Ivan Barbot, and University Psychiatric Hospital Vrapce. It was nested within the prospective cohort study: "Biomarkers in schizophrenia-integration of complementary methods in longitudinal follow up of FEP patients". The power analysis was done for the main prospective cohort study, and it was not conducted specifically for this analysis. Patients were enrolled between June 2015 and January 2017. The study protocol was approved by the Ethics Committees of the participating institutions, and all participants gave their informed consent before the inclusion. The study was conducted in accordance with World Medical Association Declaration of Helsinki 2013 (World Medical Association 2013).
Participants
Participants were recruited proportionally at the participating hospitals until the sample sizes reached 100 participants from each population. Inclusion criteria for FEP were: no history of antipsychotic use prior to admission to hospital, first episode of psychosis with the fulfillment of the criteria for psychotic episode (codes F23, F29) according to the criteria of International Classification of Disorders, 10 th revision (ICD-10) (World Health Organization 1992). Inclusion criteria for SCH were: 2 acute psychotic episodes, illness duration >5 years and fulfillment of criteria for schizophrenia spectrum disorders (code F20) according to the ICD-10 criteria (World Health Organization 1992). Exclusion criteria for both groups were: <18 years of age, mental retardation, mental illness in childhood that can present with psychosis, neurological disorders, pregnancy and lactation, organic psychosis, the use of medications that can produce psychotic reactions, comorbid alcoholism or other addictions, use of drugs (included were patients who consummated marijuana no more than 3 times a year), psychiatric confinement and legally incapacitated participants. All patients were assessed during the acute phase of the illness at up to three weeks of treatment. The neurocognitive assessment took approximately 60 minutes and solving other questionnaires additional 20 minutes. None of the participants discontinued the assessments. Sociodemographic and clinical characteristics of FEP and SCH are presented in Table 1 .
Assessment of participants and expected outcomes
Our primary outcome was the neurocognitive profile in patients with first episode psychosis and patients with schizophrenia. We used Mini Mental Status Examination (MMSE) as a screening test for overall cognitive impairment (Folstein et al. 1975 ). MMSE result was not used in the definition of latent profiles, but as the additional explanatory variable. Neurocognitive profiles were made of five neurocognitive domains assessed with a battery of neurocognitive tests representing specific domains, as described below.
Verbal memory
Verbal memory was assessed by three tests and their subtests: Rey Auditory Verbal Learning Test (RAVLT) (Schmidt 1996) , Wechsler verbal paired associates (Wechsler 1945) 
Visuospatial abilities and delayed visual recall
Two subtests of Rey-Osterrieth Complex Figure Test (Fastenau et al. 1999 ) were used for assessment of visuospatial abilities (ROCF) and delayed visual recall after 30 minutes (ROCF 30').
Language functions
Language functions were assessed by two tests: Semantic (category) and Phonetic fluency test (Semantic, Phonetic) (Lichtenberger & Kaufman 2009 ). Score was calculated from the number of words generated in each category (categories "animals", "vegetables" and "supermarket" for semantic, and letters "a" and "f" for phonetic fluency).
Secondary outcome were correlations of neurocognitive profile in both patient groups with psychopathology and quality of life. Assessments included: 1) clinical rating of symptoms: Positive and Negative Syndrome Scale, PANSS (Kay et al. 1987) 
Statistical analysis
We enrolled 100 FEP and 100 SCH. Data were missing on at least one neurocognitive test in 13 FEP and 10 SCH. Although Little's MCAR test did indicated that data were missing completely at random ( 2 =146.5; df=157; p=0.716) we did a sensitivity analysis on multiply imputed data after the main analysis done on the cases with complete data only. Abbreviations: LL = log-likelihood; np = number of free parameters; BIC = Bayesian information criterion based on loglikelihood; CAIC = Consistent Akaike's information criterion based on log-likelihood; BLRT = bootstrap likelihood ratio test between the model in row and the model in the first row above the tested one
Prior to analysis the results of four cognitive tests measuring time (STROOP, 2, 3, TMT-A, and TMT-B) were reversed by multiplying them with -1 and adding the maximum original value, so that higher values in all tests represent better cognitive functioning. To avoid multicollinearity, local dependence, and to increase reliability of measurements we did a categorical, nonlinear principal component analysis of all tests within each neurocognitive domain. In every domain only one categorical principal component was extracted. We determined the number of components within each domain by parallel analysis (Watkins 2006) . In comparison of FEP and SCH we did not perform a testing of statistical significance of the differences because the only purpose of this comparison was the detection of potential confounders of our main result. The main analysis was done by multigroup latent profile analysis of these principal components. In the first step, we analyzed configure equivalence, that is: whether the same number of latent profiles had the best fit to the data in samples from both of our targeted populations. We did this by fitted a one-class model to the data separately in both samples, then increasing the number of classes one by one and fitted each model until no further improvement could be achieved. In the second step, we analyzed the structural similarity, that is: whether the particular neurocognitive tests' results were independent of our targeted populations; whether the profiles were characterized by similar neurocognitive tests' results in both samples; whether the nature of neurocognitive profiles was similar in FEP and SCH samples. We did this by fitting model where the neurocognitive tests results' within-profile means were constrained to be equal across two samples. We evaluated different models fit to the data by lowest Bayesian information criterion based on log-likelihood (BIC), Consistent Akaike's information criterion based on log-likelihood (CAIC), significant bootstrap likelihood ratio test between the model with k and k-1 profiles (BLRT), and entropy R 2 (Finch 2015) . In both FEP and SCH sample, the models with three latent profiles had the best fit to the data (Table 2) . Therefore, the configured equivalence was confirmed. The model where the within-profile means were constrained to be equal across the two samples fitted the data better than the completely unconstrained or completely homogenous models. We accessed a local independence by the inspection of bivariate residuals. By the protocol, if>5% of participants have missing data on any neurocognitive test, we planned to do a sensitivity analysis on the data set with multiply imputed data. Multiple imputation was done by fully conditional specification of the iterative Markov chain Monte Carlo method (Rubin 2004) . Whether the data were missing completely at random was assessed by Little's MCAR test (Little 1988 ). The level of statistical significance was set at two-tailed p<0.05 and we gave all confidence intervals at 95% level. Correction for multiple testing was done by sequential Holm-Bonferroni correction. Statistical data analysis was performed by Latent GOLD version 5.1. and NCSS 11 Statistical Software (2016) (NCSS, LLC. Kaysville, Utah, USA).
RESULTS
The structural equivalence of three latent profiles across FEP and SCH samples of patients was confirmed. The three profiles were quantitatively and not qualitatively different (Table 3 , Figure 1, Figure 2) . There were no statistically significant differences among the scores of the three neurocognitive profiles in FEP
Figure 1. Neurocognitive profiles in FEP (n=87) Dina Bosnjak Kuharic, Porin Makaric, Ivana Kekin, Zarko Bajic, Maja Zivkovic, Aleksandar Savic, Drazenka Ostojic, Vlado Jukic & Martina Rojnic Kuzman: NEUROCOGNITIVE PROFILES OF PATIENTS WITH THE FIRST EPISODE OF PSYCHOSIS AND SCHIZOPHRENIA DO NOT DIFFER QUALITATIVELY: A NESTED CROSS-SECTIONAL STUDY Psychiatria Danubina, 2019; Vol. 31, No. 1, pp 43-53
There were no statistically significant differences among the scores of the three neurocognitive profiles in SCH 
NEUROCOGNITIVE PROFILES OF PATIENTS WITH THE FIRST EPISODE OF PSYCHOSIS AND SCHIZOPHRENIA DO NOT DIFFER QUALITATIVELY: A NESTED CROSS-SECTIONAL STUDY
Psychiatria Danubina, 2019; Vol. 31, No. 1, pp 43-53 According to mean neurocognitive domains' results we named them: "Best", "Medium", and "Worst". The best neurocognitive profile was significantly more prevalent in FEP, and the worst one in SCH sample. Prevalence of the medium profile was not significantly different between the two targeted populations. After adjustment for all monitored sociodemographic and clinical patients' characteristics by multinomial logistic regression, odds for the medium neurocognitive profile compared to the odds for the best one, were not significantly different between the two samples (FEP OR=0.29; 95% CI 0.07-1.21; p=0.090). However, FEP had significantly lower odds for having the worst neurocognitive profile compared to the odds of having the best one (OR=0.09; 95% CI 0.01-0.59; p=0.013).
We found statistically significant statistical difference in negative PANSS sub-scores between the three neurocognitive profiles adjusted for age and education, with the highest negative symptoms in patients with the "Worst" profile, and the lowest among those with the "Best" profiles, without differences between the FEP and SCH groups. Also, we have not found significant differences in scores of other PANSS sub-scales, quality of life, suicide ideation, impulsiveness, aggression nor depressive symptoms between the three profiles in any of the two samples (Table 4 ). There was a number of statistically significant differences in the scores of clinical tests between the FEP and SCH sample, as stated in Table 4 .
DISCUSSION
When comparing FEP to SCH, we found that three neurocognitive profile models fitted the data the best in both samples. Profile 1 ("Best"), Profile 2 ("Medium") and Profile 3 ("Worst") consisted of five neurocognitive domains (verbal memory, executive functions, attention and speed of processing, visuospatial abilities, language functions) represented with adequate neurocognitive tests. The three profiles were structurally equivalent across FEP and SCH, with differences only in the values of specific neurocognitive tests. All profile scores reflecting results were significantly better in FEP compared to SCH. Profile 3 was more frequent among SCH group and Profile 1 among FEP group. We have not found any statistically significant differences in the level of impairment among specific neurocognitive domains across the sample, but rather an overall decrease of neurocognitive abilities.
Our results may possibly indicate that the difference in neurocognitive profiles between FEP and SCH are quantitative rather than qualitative. In other words, the nature of neurocognitive deficit might not change further after the onset of psychosis, but it may reflect a certain trait of the illness that may be present in an attenuated form from the beginning of the illness. This is in line with neurodevelopmental theory of schizo- 2014) report subtle differences when comparing these patient groups with healthy controls (e.g. better results in working memory and social cognition in FEP than in SCH), but state that the overall distribution of impairment did not statistically defer between FEP and SCH group. Our results also reflect this stability with structurally identical neurocognitive profiles presented in both patient groups. It seems that after the illness onset, during the acute phase of first episode of psychosis, the full range of neurocognitive deficits is present in the same form as it is later during the course of schizophrenia.
As all neurocognitive domains show deficits in all three profiles and in both patient groups, our results may indicate a diffuse, rather than a specific localized impairment. This is partially in line with previous studies. Although majority of them agree that there is an overall neurocognitive deficit, part of the authors point out some more specific impairments. For example, some studies highlight that speed of processing is more impaired than other domains in both FEP and SCH These specific differences could be the result of heterogeneity of measures used for assessment in previous studies, with some tests possibly being more sensitive than others. Furthermore, patient samples differed across studies regarding e.g. duration of illness or treatment, phase of the illness (acute phase, remission) or recruitment type (outpatients, hospitalized patients etc.).
Although we have not found statistically significant specific domain deficits, we did observe differences in the level of impairment among specific neurocognitive domains in patients with "Worst" profile, especially among SCH, with a higher level of impairment in attention, speed of processing, visuospatial abilities and delayed visual recall. This may possibly reflect specific subgroup of patients who are characterized by more severe symptoms from their first episode. Additionally, we found significant differences in negative symptom scores between the three neurocognitive profiles, with the "Worst" profile having the highest scores on negative PANSS in patients without significant differences between FEP and SCH samples. Consequently, more severe specific neurocognitive deficits along with higher levels of negative symptoms at the beginning of illness may contribute to poorer treatment response or overall outcome of treatment in the later period in these patients. This was previously reported in literature, e. g. Milev et al. (2005) reported significant correlations between poorer neurocognitive performance in different cognitive domains and the severity of negative symptoms and recent metaanalysis by Bora & Murray (2014) reported association of the persistence of negative symptoms with lack of improvement in neurocognitive functions at follow-up. In accordance with this studies, FEP and SCH with "Worst" profile and higher negative symptoms may be especially vulnerable and may require more of differently tailored treatment approaches including specific cognitive training methods (cognitive remediation, metacognitive training, additional pharmacological agents) from the beginning of the treatment compared to FEP or SCH with "Best" neurocognitive profile.
Besides significant differences among profiles regarding negative symptoms, we found no such differences regarding other psychotic symptoms in neither of our two samples of patients. This is concordant with schizophrenia literature. Previous studies generally agree that there are no correlations between neurocognition and positive symptoms . However, our results showed no statistically significant differences between the three profiles with self-measurement scales for quality of life, aggression, depression, suicidality and impulsiveness. This is somewhat inconsistent with some of the previous studies that found that neurocognitive deficits in various domains significantly correlated with perceived quality of life (Rodriguez et al. 2015) , suicidality (Ventriglio et al. 2016) , impulsivity or aggression (Reinharth et al. 2014) . Possible explanation could be the difference in the study method, as we investigated the correlations of clinical features with the whole neurocognitive profile of single patient and not with specific neurocognitive tests and on a group level. Another explanation is in the use of self-measurement scales in our and other studies that could be biased due to different reasons, e.g. misunderstanding, exaggerating or due to social-desirability bias.
The main limitation of our study is cross-sectional design due to which we could only describe the difference between two samples assessed at the different points during the disease life-span. We have no proves that our current SCH sample will be representative for the neurocognitive profile of our FEP sample in 10 years, nor that our current FEP sample was representative for the neurocognitive profile of our SCH sample 10 years ago. Our sample may not be treated as representative for the entire Croatian population of FEP nor SCH, although there is no ground for the assumption that characteristics of our sample are systematically different in different regions of the country. Due to age differences between our FEP and SCH group, we adjusted the analysis for age, but we cannot exclude the effects of other factors not included in the study analysis, such as illness duration or medication on neurocognitive status of our patients. Another limitation is that a part of our assessments (for quality of life, suicidality, impulsiveness and aggression) are self-measurement questionnaires which results could be potentially biased at some level.
CONCLUSIONS
Presented in a profile manner, neurocognitive differences between FEP and SCH seem to be more of a quantitative than of qualitative nature, suggesting that neurocognitive symptoms are specific trait of illness, present since its beginning and progressing over time. There is a significant association of the three neurocognitive profiles with negative symptoms: patients with the "Best" profiles have the lowest negative symptoms, and those with the "Worst" profile have the highest negative symptom scores, regardless of the number of psychotic episodes (first-episode or multiepisode). There is no association between the three neurocognitive profiles with other psychotic symptoms and clinical features. Putting it into the clinical context, patients who present with the worst neurocognitive profile in the first episode may also have severe negative symptoms and possible be of particular risk for further neurocognitive decline. Thus, definition of neurocognitive profiles can help tailoring individualized treatment options. Special focus and treating with methods specifically designed for neurocognitive and negative symptoms (e.g. cognitive remediation) may possibly influence treatment outcome and warrant further investigation.
